IMD Path we are a Molecular Diagnostics Laboratory investing in the technology, information systems and business infrastructure enabling community based Pathology groups in their diagnostic mission and empowering Oncologist in both First Line and Advanced-stage cancer management of their patients.
We presently operate two facilities in Berkeley CA and Aurora CO. These labs represent our template for functional and strategic alignment in support the “local” immediate diagnostic needs of our patients as enabled by our PSI Berkeley CA regional lab, bolstered by IMD’s Academic level Esoteric Center of Excellence in Anschutz Medical Campus at the University of Colorado…IMD’s “hub and spoke” model of care for Oncology.
At IMD “value based care” is not a marketing term but to our founders, investors, collaborators, and dedicated staff’s continuous mission to define, quality care as…achieving positive patient outcomes at reasonable cost!
Dr. Bauer has been a leader in organized medicine at the local, state, and national levels representing the interests of pathologists. As CAP president from 2009 to 2011, Dr. Bauer worked to have the CAP improve educational resources to help Pathologists adapt to rapid changes in both health care delivery systems as well as in scientific and medical technologies. Later as he returned to full time clinical practice he saw many pathology practices like his own lacked the financial and technical resources to develop community based molecular diagnostic services that could be economically competitive.
Dr. Bauer joined Integrated Molecular Diagnostics Pathology in December 2017 because the IMD practice model provides a solution allowing community practices to better integrate advanced molecular diagnostics into local clinical care.
In his time at Stanford, Louis, was able to grow the Outreach Program from $2.6 million in $36 million in revenue in a span of four years. In 2013, Louis uncovered a significant diagnostic gap in the continuity of care from hospital based Oncology patients to the Outpatient setting, which became the basis for IMD’s “Collaborative Model”.
As IMD Path’s Chief Operations and Growth Officer he brings forth the same zeal and business savvy as we continue to grow and develop as an organization throughout the country.
He received his degree in Medicine from Calcutta Medical College, India, and his doctorate in Molecular Genetics from The University of Texas MD Anderson Cancer Center. He completed residency in Anatomic and Clinical Pathology and a fellowship in Pediatric Pathology at The University of Texas Southwestern Medical Center, and a fellowship in Molecular Genetic Pathology at Baylor College of Medicine. Prior to joining Empire Genomics, Dr. Chen served as Assistant Professor and Associate Director, Molecular Genetic Pathology Fellowship Program, Department of Hematopathology, Division of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center.
He has more than 15 years of experience in molecular test development, clinical molecular diagnostics, teaching, and research. He has been an Inspector, Laboratory Accreditation Program, College of American Pathologists since 2007 and has numerous peer reviewed publications.
Additionally, he has managed regional laboratory businesses in Northern California and successfully deployed various laboratory services to Monterey, Santa Cruz, Santa Clara, Contra Costa, San Mateo and Alameda counties. He then went to develop the Cytology and Pathology lab in Palo Alto to become number twenty-four on the Top 25 List of Medicare providers.
He now serves as IMD Path’s Vice President of Sales and Business Development where his business acumen continues to be utilized to produce positive results for both the IMD Path organization and its valued customers.